A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip

British Journal of Rheumatology

Volumn 35, Issue SUPPL. 1, 1996, Pages 35-38

  Linden B ^a   Distel, M ^b   Bluhmki, E ^c  

^a Eksjo Hospital   (Sweden)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Eksjö Hospital ^*

Author keywords

Cyclooxygenase; Meloxicam; NSAID; Osteoarthritis; Piroxicam

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ABDOMINAL PAIN; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; COXITIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; DYSPNEA; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH ULCER; ULCER PERFORATION;

EID: 0029870734     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/35.suppl_1.35     Document Type: Article

References (13)

1. Scott DL, Roden S, Marshall T, Kendall MJ. Variations in responses to nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol 1982;14:691-4.
2. Jobanputra B, Nuki G. Nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Curr Opin Rheumatol 1994;6:433-9.
3. Engelhardt G, Homma D, Schlegel K, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable tolerance. Inflamm Res 1995;44:423-33.
4. Engelhardt G. Meloxicam: a potent inhibitor of COX-2. Data presented at the 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy, June 6-10, 1994, p. 82.
5. Waterworth RF, Waterworth SM, Taylor KM. A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. Eur J Rheumatol Inflamm 1985;8:21-7.
6. Zizic TM, Sutton JD, Stevens MB. Long-term experience with piroxicam in osteoarthritis. Semin Arthritis Rheum 1985;14(suppl. 1):14-9.
7. Björkenheim JM, Helland J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res 1985;13:263-9.
8. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity of osteoarthritis in the hip and knee. Scand J Rheumatol 1987;65(suppl.):85-9.
9. Bundesanzeiger 1987;166-7.
10. Vetter G. A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients. Br J Clin Pract 1985;7:276-81.
11. Bellamy N, Buchanan WW, Chalmers A et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993;20:999-1004.
12. Amundsen T, Bleken L, Borkje B et al. Variation in response to naproxen and diclofenac in patients with osteoarthritis. Curr Ther Res 1993;33:793-801.
13. Berry H, Bird HA, Black C et al. A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee. Ann Rheum Dis 1992;51:238-42.